Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis.

Weiner, Maria; Goh, Su Mein; Mohammad, Aladdin; Hruskova, Zdenka; Tanna, Anisha; Bruchfeld, Annette; Selga, Daina; Chocova, Zdenka; Westman, Kerstin; Eriksson, Per; Pusey, Charles D; Tesar, Vladimir; Salama, Alan D; Segelmark, Mårten

Published in: Clinical Journal of the American Society of Nephrology

DOI: 10.2215/CJN.00480115

2015

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Title page

Title

Outcome and treatment of elderly patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis

Authors and affiliations

Maria Weiner, M.D.1; Su Mein Goh, M.D.2; Aladdin J Mohammad, M.D., Ph.D.3; Zdenka Hrušková, M.D., Ph.D.4; Anisha Tanna, M.D.5; Annette Bruchfeld, M.D., Ph.D.6; Daina Selga, M.D., Ph.D.7; Zdeňka Chocová, M.D.4; Kerstin Westman, M.D., Ph.D.7; Per Eriksson, M.D., Ph.D.8; Charles D Pusey, D.Sc., F.Med.Sci.5; Vladimír Tesař, M.D., Ph.D.4; Alan D Salama, M.B.B.S., F.R.C.P., Ph.D.2; Mårten Segelmark, M.D., Ph.D.1

1 Department of Nephrology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
2University College London Centre for Nephrology, Royal Free Hospital, London, United Kingdom
3Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden and Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, Cambridge, United Kingdom
4Department of Nephrology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
5Department of Medicine, Imperial College London, London, United Kingdom
6Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institute, Stockholm, Sweden
7Department of Nephrology, Lund University, Skåne University Hospital, Lund and Malmö, Sweden
Department of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

Corresponding author
Maria Weiner
Department of Medical and Health Sciences, Division of Drug Research
Linköping University
581 83 Linköping
Sweden
Phone: +46 10 103 00 00
Fax: +46 13 145 004
E-mail: maria.weiner@liu.se

Running title
Treatment of ANCA-vasculitis in the elderly

Key words
ANCA, glomerulonephritis, survival, vasculitis

Word count abstract: 238
Word count text: 2993
Abstract

**Background and objectives** ANCA-associated vasculitis is commonly found in elderly patients, but there are few data concerning outcome and treatment in the highest age groups.

**Design, setting, participants and measurements** Consecutive patients (n=151) presenting between 1997 and 2009 were retrospectively included from local registries in six centers in Sweden, United Kingdom and Czech Republic if diagnosed with microscopic polyangiitis or granulomatosis with polyangiitis at an age ≥75 years during the study period. Patients were followed until 2 years from diagnosis or death. Data on survival and renal function were analyzed with respect to age, sex, ANCA specificity, renal function, C-reactive protein, comorbidities and Birmingham Vasculitis Activity Score at diagnosis as well as treatment during the first month.

**Results** Median follow-up was 730 days (IQR 244-730). Overall 1-year survival was 71.5 % and 2-year survival 64.6 %. Older age, higher creatinine and lower Birmingham Vasculitis Activity Score were associated with higher mortality in multivariable analysis. Patients who were not treated with standard immunosuppressive therapy had significantly worse survival. Renal survival was 74.8 % at 1 year. No new cases of ESRD occurred during the second year. High creatinine at diagnosis was the only significant predictor of renal survival in multivariable analysis.

**Conclusions** ANCA-associated vasculitis is a disease with substantial mortality and morbidity among elderly patients. This study showed a better prognosis for those who received immunosuppressive treatment and those who were diagnosed before having developed advanced renal insufficiency.
**Introduction**

The ANCA-associated vasculitides (AAV) comprise microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA; Wegener’s) and eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss).(1, 2) AAV are predominantly diseases of older patients, and the incidence increases with age.(3, 4) Several studies have shown that the risk of death and ESRD is higher in older patients but their response to treatment differs between studies.(5, 6) Because of an increased risk of adverse events,(7) dose adjustments of cyclophosphamide have been made for age in clinical trials(8) and are recommended in guidelines.(9) Despite the fact that AAV commonly affect older patients, the outcome of MPA and GPA in the elderly population is largely unknown.(10) Many randomized trials exclude patients aged >75 years and there are few observational studies focusing on elderly patients.(11, 12) The aim of this study was to investigate demographic factors, treatment and outcome in patients aged ≥75 years presenting with MPA or GPA.

**Materials and Methods**

**Case retrieval and classification**

Consecutive patients presenting at six centers in Sweden, United Kingdom and Czech Republic between 1997 and 2009 were included. Inclusion criteria were age ≥75 years at diagnosis and a clinical diagnosis of MPA or GPA according to the European Medicines Agency algorithm during the study period.(13) Patients classified as having eosinophilic granulomatosis with polyangiitis and polyarteritis nodosa were excluded, along with secondary vasculitis, drug-induced vasculitis and anti-glomerular basement membrane disease in accordance with the exclusion criteria in the European Medicines Agency algorithm.(13) Diagnosis was confirmed by review of patient charts. The project was approved by the Ethical Review Board in Lund, Sweden.
**Participating centers**

The Swedish cohort was recruited from local vasculitis databases at the Nephrology and Rheumatology Departments at Linköping University Hospital (catchment area 430,000 inhabitants)(14), the Nephrology and Rheumatology Departments at Skåne University Hospital in Lund and Malmö (700,000 inhabitants)(3) and the Nephrology Department at Karolinska University Hospital (1.5 million inhabitants).

The English cohort was recruited from a local database at the Imperial College Renal and Transplant Centre (2 million inhabitants) and from vasculitis and renal pathology databases at the Nephrology Department at Royal Free Hospital (1.4 million inhabitants) in London.

The Czech cohort was recruited from the Department of Nephrology at General University Hospital in Prague (tertiary national referral center with catchment area for vasculitis about 5 million inhabitants), using a local database transferred into a nationwide registry in 2009.

**Data collection**

The following data were collected retrospectively from time of diagnosis: date of diagnosis, age, sex, diagnosis type (MPA/GPA), ANCA specificity, C-reactive protein, creatinine (at diagnosis or before start of dialysis in patients dialysis dependent at diagnosis), dialysis dependency, disease activity according to Birmingham Vasculitis Activity Score (BVAS)(15) and major comorbidities. Data on outcome up to 2 years from diagnosis included day of death and ESRD. Data on treatment during the first 3 months from diagnosis included cumulative dose of pulse steroids, oral steroids and cyclophosphamide, treatment with rituximab or other cytotoxic agents, and use of plasma exchange. Based on the treatment issued during the first month, patients surviving that point were divided into groups. Patients were assigned to the rituximab group if they were receiving any dose of rituximab. Patients were assigned to the
oral cyclophosphamide group or the intravenous cyclophosphamide group if they were issued a minimum cumulative dose of 2000 mg oral or 1500 mg intravenous cyclophosphamide, respectively, during the first 3 months. Patients who were given less cyclophosphamide or treated with azathioprine, mycophenolate or methotrexate were assigned to “other regimen” group, whereas patients were assigned to the “steroids only” group if they were given a daily dosage of ≥30 mg of prednisolone. The remaining patients were placed in the “untreated” group. For each group, the proportion of patients given pulse steroids (cumulative dose ≥250 mg) or plasma exchange was recorded. The effect of treatment on survival and renal survival was estimated using an intention-to-treat approach starting on day 30.

Date of diagnosis was defined as follows: start of treatment with prednisolone ≥30 mg/day, plasma exchange or cyclophosphamide; if never treated, the day of biopsy; and if no biopsy, the day of the first positive ANCA test result. A dipstick value of ≥2 was taken as representative of hematuria equal to 10 red blood cells per high-power field when assessing BVAS. Indirect immunofluorescence or antigen-specific ELISA was used to detect ANCA. ESRD was defined as need for dialysis for >90 days. Comorbidities were registered essentially as described by Davies et al (16) with 1 point each given for malignancy, ischemic heart disease, peripheral vascular disease, heart failure, diabetes, systemic inflammatory disease (excluding AAV), pulmonary disease and cirrhosis.

Statistical analyses

Statistical analysis was performed using SPSS Statistics for Windows software (version 21.0; IBM Corp., Armonk, NY). P-values <0.05 were considered significant. Double-positive patients were designated as having either myeloperoxidase-ANCA (MPO-ANCA)/perinuclear ANCA (P-ANCA) or proteinase-3-ANCA (PR3-ANCA)/cytoplasmic ANCA (C-ANCA) depending on the highest titer. Differences between groups were analyzed.
using the Mann-Whitney or Kruskal-Wallis test for non-parametric data and the chi-squared or Fisher’s exact test for categorical data. All analyses exclude missing data. The Kaplan-Meier method was used to estimate overall and renal survival, and the log-rank test used to evaluate differences between groups. Censoring was performed at the day of loss to or completion of follow-up. Estimates of renal survival were censored for death. In analysis of treatment, patients who died within the first 30 days after diagnosis were excluded. Cox proportional hazards models were used to analyze variables at diagnosis and their association with overall survival and renal survival. Variables included were age, sex, ANCA specificity, BVAS, creatinine, C-reactive protein and comorbidity index. In a second model, a treatment variable was included. Patients in the intravenous cyclophosphamide/oral cyclophosphamide and rituximab groups were considered to have received standard immunosuppressive therapy and were compared with those who had not received such treatment. The standardized mortality ratio (SMR) was calculated for the group aged 75-84 years comparing the observed death rates in the Swedish cohorts with expected death rates in the general Swedish population matched for age and calendar year. The death rate for the general population was calculated using life tables from 2004 provided by Statistics Sweden (http://www.scb.se).

Results

Baseline patient characteristics

A total of 151 patients were included in this study, and their characteristics at diagnosis are shown in Table 1. Median age at diagnosis was 79 years (interquartile range [IQR] 77-82). MPA was diagnosed in 70% of the patients and GPA in 30%. MPO-ANCA/P-ANCA-positivity was seen in 60%, PR3-ANCA/C-ANCA-positivity in 36%, double-positivity in 1% and ANCA negativity in 3%. Renal involvement (according to BVAS) was seen in 92% of the patients, more commonly in patients with MPA (P<0.001). Biopsy was performed in 113
patients (76.4%; data missing in three patients), of these 96 (85.0%) were renal biopsies. Most parameters showed no significant differences between the three participating countries. However, dialysis dependency at diagnosis was seen in 16% in the Swedish cohort, compared to 44% in the English cohort and 60% in the Czech cohort (P<0.001). Comorbidities were more common in Czech patients; only 16% had no comorbidities compared to 47% and 40% of the Swedish and English patients, respectively (P<0.001). Median BVAS was 12 (IQR 9-12) in patients with renal-limited disease and 16 (IQR 13-19) in patients with more than one organ system involved (P<0.001).

**Treatment**

In total, seven patients died during the first month, and an additional 14 were excluded because of insufficient treatment data, leaving 130 patients for analysis of treatment. Characteristics for the different treatment groups are shown in Table 2. There were no significant differences between patients receiving standard immunosuppressive therapy (oral cyclophosphamide, intravenous cyclophosphamide, and rituximab groups) and those not receiving such therapy (other regimens, steroids only, or untreated groups) with regard to creatinine, BVAS, proportion of dialysis dependency, or proportion of patients with at least one comorbid condition at diagnosis. Likewise, there were no significant differences between the participating countries (Supplemental Table S1). The median cumulative dose of intravenous cyclophosphamide during the first 3 months in the standard treatment group was 3000 mg (IQR 2100-4500) and the corresponding figure for oral cyclophosphamide was 5270 mg (IQR 3100-6950).

**Survival**
Patients were followed until 2 years after diagnosis or death. Six patients (all from England) were lost to follow-up, within a median time of 69 days (IQR 34-140). One-year overall survival was 71.5% and 2-year survival 64.6%. During the first 3 months after diagnosis 22 patients (14.6%) died. Older age, higher creatinine and lower BVAS at diagnosis were independent factors associated with higher mortality by univariable (Figure 1; Supplemental Table S2) as well as multivariable analysis (Table 3). Two-year survival was 36.0% in the Czech Republic, 66.7% in Sweden and 80.2% in the United Kingdom (P=0.001). Dialysis at diagnosis was not significantly associated with survival (hazard ratio [HR], 1.57 95% confidence interval [CI], 0.90 to 2.74, P=0.12). Out of the 37 patients who developed ESRD, 18 (48.6%) died during follow-up compared to 34 of the 114 patients (29.8%) who did not develop ESRD. The SMR in patients aged 75-84 years in the Swedish cohort was 3.69 (95% CI 2.45 to 5.55) after 2 years. The SMR was 5.04 (95% CI, 3.13 to 8.11) in the first year and 1.86 (95% CI, 0.77 to 4.47) in the second year. Survival was significantly worse in patients not treated with standard immunosuppressive therapy compared to patients treated with either cyclophosphamide or rituximab (Figure 2). Two-year survival was 72.9% for patients treated with oral cyclophosphamide, 72.5% for intravenous cyclophosphamide, 81.3% for rituximab and 45.0% for no/other treatment. When including treatment in the survival analysis, age, creatinine and treatment remained significant predictors of mortality in both univariable and multivariable analyses, but BVAS lost its significance in the multivariable analysis (Table 4, Supplemental Table S3). The results remained essentially unchanged when including patients with lower cumulative doses of cyclophosphamide in the cyclophosphamide treatment group (HR, 0.30; 95% CI, 0.11 to 0.80; P=0.02).

Renal function
Dialysis was needed in 45 patients (30.6%) at the time of diagnosis. Twelve of these (26.7%) recovered independent renal function during follow-up. By the end of the first year, a total of 37 patients (24.5%) had developed ESRD. No new cases of ESRD occurred during the second year. Renal survival censored for death was 74.8%. It was 35.2% for the Czech cohort, 88.2% for the Swedish cohort and 71.1% for the English cohort (P<0.001). In multivariable analysis, creatinine level at diagnosis was the only significant predictor of renal survival (HR, 4.10; 95% CI, 2.25 to 7.49 per quartile increase in serum creatinine; P<0.001; Figure 3), whereas treatment was not significantly associated with renal outcome (HR, 1.88; 95% CI, 0.61 to 5.77; P=0.27). In the subgroup of patients dialysis dependent at diagnosis, nine of the 11 (81.8%) who recovered renal function were treated with plasma exchange, as compared with 14 of the 26 (53.8%) who did not recover renal function (P=0.15).

**Discussion**

In this study, we show that AAV in older patients is a severe condition with high mortality and morbidity during the first year after diagnosis. Despite the significant burden of disease, we found a relatively favorable outcome for those who survive the first year. To our knowledge, this is the largest study of patients ≥75 years with AAV.

We found older age, high creatinine and low BVAS to be predictors of worse survival. High age and impaired renal function have previously been shown to predict mortality in younger age groups as well.(6, 11, 14, 17-20) The inverse relationship between BVAS and survival is intriguing and opposite of some previous findings.(11, 18) Because the vast majority of patients in our study had renal involvement at diagnosis, patients with a high BVAS had both renal and extrarenal symptoms, whereas those with renal-limited disease fell in the low BVAS group. It is possible that patients with few extra-renal symptoms are diagnosed at a
later stage with more irreversible renal damage and worse survival. However, this association needs to be confirmed in other studies and the cause remains to be elucidated.

Survival was significantly worse in those not treated with standard doses of cyclophosphamide or rituximab. There is a risk of confounding by indication when analyzing treatment data in retrospective studies (in this case, that frail patients receive less treatment), and we did not have data on the detailed clinical context including the goals and preferences of patients or the treating physician’s motive for therapy decisions. To reduce this effect we did not include deaths occurring during the first month and used an intention-to-treat approach, reasoning that standard therapy given during the first month was intended to continue according to modern guidelines,(9, 21) whereas this was not the case when such therapy was not issued during the first month. It is, however, difficult to rule out the possibility that some patients who originally received immunosuppressive treatment developed complications and that therapy was stopped. The worse prognosis in these patients would thus be caused by early adverse events. However, also when considering all cyclophosphamide use as intention-to-treat with standard therapy, there was a clear survival benefit for standard therapy. The unfavorable prognosis in those treated less aggressively cannot readily be explained by more comorbidities, worse renal function or differences in disease activity at diagnosis, because these parameters did not differ significantly between the groups. However, this does not exclude the possibility that some patients were still considered frail and not suitable for immunosuppressive therapy. The best survival was seen in patients treated with rituximab; however the number of patients was rather small and no rituximab was given in the Czech cohort with the worst survival rate. Hence, this result should be interpreted with care.

The survival differences between countries may, at least partly, be explained by selection bias. The Department of Nephrology in Prague is a tertiary referral center receiving the most
severe cases of AAV. Additionally, the Czech patients had more comorbidities and more often had advanced renal insufficiency at diagnosis. Opposite to our results, others have reported dialysis at diagnosis to be an independent factor for survival(20) and it is possible that our analysis did not fully compensate for this factor. Comorbidities were not associated with mortality in the entire cohort, but reached borderline significance in the analysis including treatment. In our cohort, 15% of the patients had a previous malignancy before the diagnosis of AAV. This is similar to other studies showing a frequency of malignancies of 8-16%.(17, 22) The life expectancy at birth was 75.3 years in the Czech Republic in 2003, compared to 78.3 years in the United Kingdom and 80.2 years in Sweden.(23) The effect of differences in life expectancies in the general population when comparing the survival of AAV is difficult to discern.

One-year survival was 72% and 2-year survival was 65% in this study compared with 82-88% and 82-85%, respectively in previous studies.(2, 17, 18) We also show that survival in the Swedish cohort was significantly worse compared to the background population during the first year after diagnosis, but was not significantly worse during the second year. Together with the fact that no new cases of ESRD occurred during the second year, this implies a fairly good prognosis if patients survive the first year.

Importantly, we found that elderly patients usually present with significant renal involvement and a predominance of clinical MPA and MPO-ANCA/P-ANCA positivity. This is consistent with the finding that patients with MPA are older than patients with GPA and that patients with MPO/P-ANCA are older than patients with PR3/C-ANCA.(5, 6, 11, 18, 24, 25) Results showing that older patients with GPA have more renal insufficiency and less upper airway symptoms(26) add to this picture. We found a higher proportion of MPO/P-ANCA positive GPA as compared to two large studies in Caucasian patients. In our cohort, 24% of patients with GPA were positive for MPO/P-ANCA compared with 9% and 10%, respectively, in a
follow-up of patients from four European Vasculitis Study Group trials and a large genetic study in Europe.(18, 27)

High creatinine at presentation is a well-known risk factor for impaired renal survival(2, 12, 17, 28, 29), and we confirmed this in older patients. High creatinine at diagnosis was the only significant predictor of renal survival in multivariable analysis, and treatment with immunosuppressive agents was not significantly associated with renal survival. Most patients reaching ESRD were dialysis dependent at presentation and conceivably already had irreversible renal damage at the time of diagnosis. Increased awareness of these conditions in the elderly and early recognition is probably important for improved renal survival. Plasma exchange has been shown to reduce the risk of progression to ESRD in patients with severe renal impairment at diagnosis.(30) In accordance with this, we found a tendency towards better renal survival in those treated with plasma exchange in the subgroup of patients who were dialysis dependent at diagnosis.

Our study has several limitations. The greatest limitation is the retrospective nature of the data and the risk of introducing bias related to this, as discussed above. A possible limitation is that the centers in Linköping and Lund received both rheumatology and nephrology patients, whereas London received relatively more nephrology patients and Stockholm and Prague almost exclusively received patients with renal involvement. However, referral bias cannot explain the large proportion of patients with MPA and renal involvement because this did not differ significantly between countries. Because of the heterogeneity of referral patterns in the participating centers, our results are difficult to generalize to sites with different patient characteristics. We did not have any data on renal histology, so we could not analyze whether this was predictive of outcome.
In conclusion, we demonstrate in a large cohort of elderly patients with AAV that survival is significantly better in patients who are treated with adequate doses of cyclophosphamide or rituximab at diagnosis compared with patients who receive less aggressive treatment.

**Disclosures**

None.

**Acknowledgements**

The authors thank Qianwen Ko for acquisition of data from Royal Free Hospital.

This study was supported by grants from the Ingrid Asp Foundation, the Swedish Renal Foundation and the NIHR Imperial Biomedical Research Centre.

References


17. Westman KW, Selga D, Isberg PE, Bladstrom A, Olsson H: High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked


## Tables

### Table 1. Demographic factors at the time of diagnosis divided according to country and diagnosis type.

<table>
<thead>
<tr>
<th>Variables</th>
<th>All n=151</th>
<th>Sweden 58% (n=87)</th>
<th>United Kingdom 26% (n=39)</th>
<th>Czech Republic 16% (n=25)</th>
<th>P value</th>
<th>MPA 70% (n=105)</th>
<th>GPA 30% (n=46)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>50% (76)</td>
<td>55% (48)</td>
<td>54% (21)</td>
<td>28% (7)</td>
<td>0.05</td>
<td>47% (49)</td>
<td>59% (27)</td>
<td>0.17</td>
</tr>
<tr>
<td>Female</td>
<td>50% (75)</td>
<td>45% (39)</td>
<td>46% (18)</td>
<td>72% (18)</td>
<td></td>
<td>53% (56)</td>
<td>41% (19)</td>
<td></td>
</tr>
<tr>
<td>Age (median)</td>
<td>79 (77-82)</td>
<td>79 (77-83)</td>
<td>78 (77-82)</td>
<td>78 (77-82)</td>
<td>0.69</td>
<td>79 (77-82)</td>
<td>78 (76-81)</td>
<td>0.16</td>
</tr>
<tr>
<td>Age &lt;80 years</td>
<td>54% (82)</td>
<td>52% (45)</td>
<td>56% (22)</td>
<td>60% (15)</td>
<td>0.73</td>
<td>51% (54)</td>
<td>61% (28)</td>
<td>0.28</td>
</tr>
<tr>
<td>Age ≥80 years</td>
<td>46% (69)</td>
<td>48% (42)</td>
<td>44% (17)</td>
<td>40% (10)</td>
<td>0.32</td>
<td>49% (51)</td>
<td>39% (18)</td>
<td></td>
</tr>
<tr>
<td><strong>ANCA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPO/P-ANCA</td>
<td>60% (89)</td>
<td>58% (50)</td>
<td>58% (22)</td>
<td>71% (17)</td>
<td>0.48</td>
<td>75% (78)</td>
<td>24% (11)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PR3/C-ANCA</td>
<td>36% (53)</td>
<td>39% (34)</td>
<td>32% (12)</td>
<td>29% (7)</td>
<td>0.56</td>
<td>18% (19)</td>
<td>76% (34)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Double-positive</td>
<td>1% (2)</td>
<td>2% (2)</td>
<td>0% (0)</td>
<td>0% (0)</td>
<td>&gt;0.99</td>
<td>2% (2)</td>
<td>0% (0)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>Negative</td>
<td>3% (5)</td>
<td>1% (1)</td>
<td>10% (4)</td>
<td>0% (0)</td>
<td>0.02</td>
<td>5% (5)</td>
<td>0% (0)</td>
<td>0.32</td>
</tr>
<tr>
<td>Creatinine mg/dL</td>
<td>3.20 (1.72-5.18)</td>
<td>2.93 (1.57-4.33)</td>
<td>4.33 (2.43-5.85)</td>
<td>4.47 (2.71-6.64)</td>
<td>0.06</td>
<td>3.76 (2.74-5.69)</td>
<td>2.04 (0.97-3.25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CRP mg/L</td>
<td>75 (18-134)</td>
<td>99 (27-139)</td>
<td>38 (8-124)</td>
<td>68 (22-120)</td>
<td>0.07</td>
<td>62 (15-123)</td>
<td>119 (50-156)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BVAS4</td>
<td>15 (12-19)</td>
<td>16 (13-20)</td>
<td>12 (9-14)</td>
<td>14 (13-17)</td>
<td>&lt;0.001</td>
<td>14 (12-18)</td>
<td>17 (13-21)</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Organ involvement</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General</td>
<td>63% (82)</td>
<td>76% (66)</td>
<td>21% (4)</td>
<td>48% (12)</td>
<td>&lt;0.001</td>
<td>62% (56)</td>
<td>65% (26)</td>
<td>0.71</td>
</tr>
<tr>
<td>Cutaneous</td>
<td>9% (12)</td>
<td>7% (6)</td>
<td>11% (2)</td>
<td>16% (4)</td>
<td>0.27</td>
<td>10% (9)</td>
<td>8% (3)</td>
<td>0.76</td>
</tr>
<tr>
<td>Mucous/eyes</td>
<td>5% (7)</td>
<td>5% (4)</td>
<td>11% (2)</td>
<td>4% (1)</td>
<td>0.43</td>
<td>0% (0)</td>
<td>18% (7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ENT</td>
<td>15% (20)</td>
<td>20% (17)</td>
<td>5% (1)</td>
<td>8% (2)</td>
<td>0.22</td>
<td>3% (3)</td>
<td>43% (17)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Chest</td>
<td>34% (44)</td>
<td>36% (31)</td>
<td>11% (2)</td>
<td>44% (11)</td>
<td>0.05</td>
<td>25% (23)</td>
<td>53% (21)</td>
<td>0.002</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>5% (7)</td>
<td>8% (7)</td>
<td>0% (0)</td>
<td>0% (0)</td>
<td>0.30</td>
<td>4% (4)</td>
<td>8% (3)</td>
<td>0.44</td>
</tr>
<tr>
<td>Abdominal</td>
<td>3% (4)</td>
<td>5% (4)</td>
<td>0% (0)</td>
<td>0% (0)</td>
<td>0.77</td>
<td>3% (3)</td>
<td>3% (1)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>Renal</td>
<td>92% (121)</td>
<td>90% (78)</td>
<td>100% (19)</td>
<td>96% (24)</td>
<td>0.23</td>
<td>98% (89)</td>
<td>80% (32)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Nervous system</td>
<td>16% (21)</td>
<td>22% (19)</td>
<td>0% (0)</td>
<td>8% (2)</td>
<td>0.02</td>
<td>15% (14)</td>
<td>18% (7)</td>
<td>0.76</td>
</tr>
<tr>
<td>Dialysis dependency</td>
<td>31% (45)</td>
<td>16% (14)</td>
<td>44% (16)</td>
<td>60% (15)</td>
<td>&lt;0.001</td>
<td>34% (35)</td>
<td>22% (10)</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>Comorbidity score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>40% (61)</td>
<td>47% (41)</td>
<td>40% (16)</td>
<td>16% (4)</td>
<td>0.02</td>
<td>36% (38)</td>
<td>50% (28)</td>
<td>0.11</td>
</tr>
</tbody>
</table>
Values are presented as % (n) or median (interquartile range) and exclude missing data. ¹Data missing in two patients; ²data missing in nine patients; ³data missing in six patients; ⁴data missing in four patients; ⁵data missing in 20 patients; ⁶data missing in four patients.

MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; ANCA, anti-neutrophil cytoplasm antibodies; MPO, myeloperoxidase; PR3, proteinase-3; CRP, C-reactive protein; BVAS, Birmingham Vasculitis Activity Score; ENT, ear-nose-throat; IHD, ischemic heart disease
Table 2. Groups of patients based on the treatment given during the first month after diagnosis: Contribution to the treatment groups by the participating countries (A), baseline characteristics (B) and additional therapy (C).

<table>
<thead>
<tr>
<th></th>
<th>CYC oral</th>
<th>CYC iv</th>
<th>Rituximab</th>
<th>Steroids only</th>
<th>Other</th>
<th>Untreated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>35.4% (n=46)</td>
<td>30.8% (n=40)</td>
<td>12.3% (n=16)</td>
<td>1.5% (n=2)</td>
<td>14.6% (n=19)</td>
<td>5.4% (n=7)</td>
</tr>
<tr>
<td>Countries</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweden (n=81)</td>
<td>30.9% (25/81)</td>
<td>35.8% (29/81)</td>
<td>8.6% (7/81)</td>
<td>2.5% (2/81)</td>
<td>14.8% (12/81)</td>
<td>7.4% (6/81)</td>
</tr>
<tr>
<td>United Kingdom (n=25)</td>
<td>52.0% (13/25)</td>
<td>0.0% (0/25)</td>
<td>36.0% (9/25)</td>
<td>0.0% (0/25)</td>
<td>12.0% (3/25)</td>
<td>0.0% (0/25)</td>
</tr>
<tr>
<td>Czech Republic (n=24)</td>
<td>33.3% (8/24)</td>
<td>45.8% (11/24)</td>
<td>0.0% (0/24)</td>
<td>0.0% (0/24)</td>
<td>16.7% (4/24)</td>
<td>4.2% (1/24)</td>
</tr>
<tr>
<td>Clinical variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>79 (77-81)</td>
<td>78 (77-81)</td>
<td>79 (78-81)</td>
<td>78 (76-79)</td>
<td>83 (78-85)</td>
<td>80 (77-81)</td>
</tr>
<tr>
<td>MPO</td>
<td>76.1% (35/46)</td>
<td>59.0% (23/39)</td>
<td>37.5% (6/16)</td>
<td>100% (2/2)</td>
<td>47.4% (9/19)</td>
<td>85.7% (6/7)</td>
</tr>
<tr>
<td>PR3</td>
<td>21.7% (10/46)</td>
<td>41.0% (16/39)</td>
<td>56.3% (9/16)</td>
<td>0.0% (0/2)</td>
<td>52.6% (10/19)</td>
<td>14.3% (1/7)</td>
</tr>
<tr>
<td>Creatinine mg/dL</td>
<td>4.04 (2.68-4.92)</td>
<td>2.00 (1.13-3.69)</td>
<td>3.01 (2.00-4.28)</td>
<td>8.89 (2.29-15.49)</td>
<td>4.02 (2.69-5.96)</td>
<td>2.99 (2.05-6.24)</td>
</tr>
<tr>
<td>Dialysis</td>
<td>37.8% (17/45)</td>
<td>17.5% (7/40)</td>
<td>31.3% (5/16)</td>
<td>50.0% (1/2)</td>
<td>26.3% (5/19)</td>
<td>28.6% (2/7)</td>
</tr>
<tr>
<td>VAS</td>
<td>14 (12-19)</td>
<td>15 (14-20)</td>
<td>14 (9-21)</td>
<td>15 (14-15)</td>
<td>16 (13-19)</td>
<td>12 (5-17)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>71.7% (33/46)</td>
<td>57.5% (23/40)</td>
<td>50.0% (8/16)</td>
<td>0.0% (0/2)</td>
<td>63.2% (12/19)</td>
<td>71.4% (5/7)</td>
</tr>
<tr>
<td>Treatment variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse steroids</td>
<td>28.3% (13/46)</td>
<td>55.0% (22/40)</td>
<td>56.3% (9/16)</td>
<td>0.0% (0/2)</td>
<td>31.6% (6/19)</td>
<td>0.0% (0/7)</td>
</tr>
<tr>
<td>Plasma exchange</td>
<td>26.1% (12/46)</td>
<td>27.5% (11/40)</td>
<td>46.7% (7/15)</td>
<td>50.0% (1/2)</td>
<td>26.3% (5/19)</td>
<td>14.3% (1/7)</td>
</tr>
</tbody>
</table>

Values are presented as % (n) or median (interquartile range) and exclude missing data. 1Data missing in one patient; 2data missing in six patients; 3patients with ≥ 1 comorbid condition at diagnosis; 4other cytotoxic agents or cumulative cyclophosphamide dose <2000 mg oral cyclophosphamide/≤1500 mg intravenous cyclophosphamide during the first 3 months.
CYC, cyclophosphamide MPO, myeloperoxidase; PR3, proteinase-3; BVAS, Birmingham Vasculitis Activity Score
Table 3. Multivariable Cox regression analysis of overall 2-year survival in the entire cohort\(^1\).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hazard ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per year)</td>
<td>1.13 (1.06-1.21)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male sex</td>
<td>1.20 (0.65-2.18)</td>
<td>0.56</td>
</tr>
<tr>
<td>BVAS (per point)</td>
<td>0.92 (0.86-0.98)</td>
<td>0.01</td>
</tr>
<tr>
<td>MPO/P-ANCA</td>
<td>0.67 (0.37-1.24)</td>
<td>0.20</td>
</tr>
<tr>
<td>CRP (per quartile)</td>
<td>1.13 (0.85-1.51)</td>
<td>0.39</td>
</tr>
<tr>
<td>Creatinine (per quartile)</td>
<td>1.35 (1.03-1.76)</td>
<td>0.03</td>
</tr>
<tr>
<td>Comorbidity score (per point)</td>
<td>1.22 (0.84-1.78)</td>
<td>0.30</td>
</tr>
</tbody>
</table>

\(^1\) Individual data missing in 15 patients, analysis performed on a total of 136 patients.

CI, confidence interval; BVAS, Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; P-ANCA, perinuclear anti-neutrophil cytoplasm antibodies; CRP, C-reactive protein
Table 4. Multivariable Cox regression analysis of overall 2-year survival in patients with complete treatment data available.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Hazard ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per year)</td>
<td>1.13 (1.04-1.23)</td>
<td>0.003</td>
</tr>
<tr>
<td>Male sex</td>
<td>1.37 (0.69-2.73)</td>
<td>0.37</td>
</tr>
<tr>
<td>BVAS (per point)</td>
<td>0.94 (0.88-1.01)</td>
<td>0.09</td>
</tr>
<tr>
<td>MPO/P-ANCA</td>
<td>0.74 (0.36-1.51)</td>
<td>0.41</td>
</tr>
<tr>
<td>CRP (per quartile)</td>
<td>1.01 (0.72-1.42)</td>
<td>0.95</td>
</tr>
<tr>
<td>Creatinine (per quartile)</td>
<td>1.40 (1.02-1.92)</td>
<td>0.04</td>
</tr>
<tr>
<td>Comorbidity score (per point)</td>
<td>1.48 (0.97-2.26)</td>
<td>0.07</td>
</tr>
<tr>
<td>Treatment&lt;sup&gt;2&lt;/sup&gt;</td>
<td>0.40 (0.19-0.87)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

<sup>1</sup>Individual data missing in 11 patients, analysis performed on a total of 119 patients. <sup>2</sup>Rituximab or cyclophosphamide at minimum dose 2000 mg oral/1500 mg intravenous during the first 3 months.

CI, confidence interval; BVAS, Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; P-ANCA, perinuclear anti-neutrophil cytoplasm antibodies; CRP, C-reactive protein
Figure legends

Figure 1. Patient survival

Kaplan-Meier plot depicting overall 2-year survival divided according to age, creatinine level, and BVAS. (A) Age at diagnosis ≥80 years (n=69) vs. <80 years (n=82); (B) Creatinine level at diagnosis equal to/above median (≥3.20 mg/dL) (n=71) vs. creatinine below median (<3.20 mg/dL) (n=71); (C) BVAS at diagnosis ≥15 (n=74) vs. BVAS <15 (n=73). BVAS, Birmingham Vasculitis Activity Score.

Figure 2. Treatment

Kaplan-Meier plot depicting overall 2-year survival divided according to the treatment given during the first month after diagnosis. CYC/RTX indicates rituximab or cyclophosphamide at minimum dose 2000 mg oral/1500 mg intravenous during the first 3 months (n=102), whereas no/other treatment indicates other regimens, steroids only or untreated (n=28). Number at risk starting on day 30.

Figure 3. Renal survival

Kaplan-Meier plot depicting renal survival censored for death divided according to serum creatinine at diagnosis. First quartile 0.69-1.73 mg/dL (n=37); second quartile 1.74-3.34 mg/dL (n=38); third quartile 3.35-5.67 mg/dL (n=37); fourth quartile 5.68 mg/dL-dialysis dependency (n=37).
A

Overall survival

- age <80 years
- age ≥80 years

Days from diagnosis

At risk
<80  82  65  62  58  
≥80  69  51  42  36  

B

Overall survival

- creatinine <3.20 mg/dL
- creatinine ≥3.20 mg/dL

Days from diagnosis

At risk
<3.20  71  58  54  50  
≥3.20  71  52  45  40  

C

Overall survival

- BVAS <15
- BVAS ≥15

Days from diagnosis

At risk
<15  73  52  45  39  
≥15  74  61  56  52  

p=0.02
p=0.03
p=0.04
Percent renal survival

Days from diagnosis

At risk

<table>
<thead>
<tr>
<th>Quartile</th>
<th>1st</th>
<th>2nd</th>
<th>3rd</th>
<th>4th</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>37</td>
<td>31</td>
<td>29</td>
<td>28</td>
</tr>
<tr>
<td>2nd</td>
<td>38</td>
<td>27</td>
<td>23</td>
<td>20</td>
</tr>
<tr>
<td>3rd</td>
<td>37</td>
<td>22</td>
<td>21</td>
<td>19</td>
</tr>
<tr>
<td>4th</td>
<td>37</td>
<td>7</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

p<0.001